🔬✨ mProbe Inc. x ACTG — Combining Proteomics & Genomics for a New Era of Precision Oncology 🚀 Exciting news! mProbe Inc., a leader in clinical proteomics, is partnering with ACT Genomics (ACTG), Asia’s foremost provider of next-generation sequencing (NGS) precision oncology, to integrate Proteogenomics into cancer treatment. This collaboration enhances molecular insights into tumor biology, empowering oncologists with more comprehensive multi-omic data for precise and personalized treatment strategies. With ACTG officially becoming the exclusive master distributor of OncoOmicsDX in Asia, this partnership marks a major step toward advancing precision oncology across Taiwan, Hong Kong, Macau, Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines. 📌 https://lnkd.in/gm9W9gD7 🔗 Together, we are revolutionizing cancer care through Proteogenomics! #PrecisionMedicine #Proteogenomics #Oncology #ClinicalProteomics #NGS #MultiOmics #CancerBiomarkers #PersonalizedMedicine #CancerResearch #OncoOmicsDX — 🔬✨ mProbe Inc. x ACTG — 蛋白質體學 x 基因體學，開啟癌症精準醫療新時代 🚀 最新合作消息！ 臨床蛋白質體學技術領導者 mProbe Inc. 攜手 亞洲領先的 NGS 精準腫瘤學服務提供者 ACT Genomics（ACTG），透過 Proteogenomics 整合蛋白質體學與基因體學，為癌症治療帶來更深入的分子層級洞察，幫助腫瘤科醫師制定更精準的個人化治療策略。 🎉 ACTG 現正式成為 OncoOmicsDX 在亞洲的獨家總代理，這項合作將推動 精準腫瘤學 在 台灣、香港、澳門、新加坡、泰國、馬來西亞、印尼、越南與菲律賓的發展，讓更多醫療機構和患者受益。 📌 https://lnkd.in/g8hkCWeb 🔗 攜手推動 Proteogenomics，讓癌症治療更精準！ #精準醫療 #Proteogenomics #腫瘤學 #臨床蛋白質體學 #NGS #多組學 #癌症標誌物 #個人化醫療 #癌症研究 #OncoOmicsDX
关于我们
At mProbe we are transforming the fields of precision health and precision medicine with molecular diagnostic tools and analysis to improve disease risk screening and intervention effectiveness when compared to the current standards of care. Clinical outcomes matter most, but biology changes first. We have harnessed the ability to measure changes at the systems biology level so that disease onset, progression and care efficacy can be determined long before other clinical indicators- like weight loss, blood pressure, even blood chemistry - change. Our molecular tests facilitate the choice of optimized interventions based upon patient’s risk and matched to the individual’s biology providing the highest likelihood of success. mProbe utilizes our proprietary technology combination of artificial intelligence and multi-omic diagnostics to predict, prevent and cure disease precisely. mProbe has developed four product lines encompassing Precision Cancer Care, Precision Maternal/Child Care, Precision Health and Wellness, and Healthcare Analytics. In Precision Cancer Care we help oncologists choose the most efficacious chemotherapies and targeted therapies based on the individual’s tumor biology. In Precision Maternal/Child Care, we measure healthy pregnancy progression and predict preterm birth and preeclampsia allowing families and their physicians to take preventive steps. We also provide precision diagnostics for diseases such as Kawasaki Diseases, etc. In Precision Health and Wellness, we predict chronic diseases and their complications with absolute probabilities enabling physicians and patients to take the necessary preventive steps. In Healthcare Analytics, through HBI Solutions' state of art machine learning and artificial intelligence, we offer breakthrough predictive risk technologies, cost reduction and quality measurement solutions to hospitals, pharmaceutical companies, regional health systems, and insurance companies
- 网站
-
http://www.mprobe.com
mProbe Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 51-200 人
- 总部
- Mountain View，California
- 类型
- 私人持股
- 领域
- healthcare、big data、proteomics、metabolomics、diagnostics、AI、multiomics、preventative、population health、predictive analytics、precision oncology和precision health
地点
mProbe Inc.员工
动态
-
🌟 雲檢祝您蛇年農曆新年快樂！ 🌟 橫批：精準安康 上聯：雲織吉祥連四海 下聯：檢準健康福滿堂 感謝您對雲檢醫學mProbe 的支持與信任！ 新的一年，我們將繼續致力於以精準檢測守護健康，讓大家享受專屬的安康與福氣。 祝大家蛇年蛇麼都如意、事事順心！ #mProbe #PrecisionHealth #PrecisionMedicine #MetaGuard #OmcoOmicsDx #SubHealth
-
-
🎉 2025 新年快樂！🎉 💝與 mProbe 一起，讓健康走在時間的前面！ 🔆新的一年，從了解自己的 生理年齡 開始，掌握 亞健康風險，預防 癌前變化，並以最精準的 癌症用藥指引 開啟希望。我們相信，健康的未來始於每一個數據和決策。 ㊗️mProbe 祝福您新的一年：健康有依據，決策更安心，人生更精彩！ ✅一起探索，讓科學引領未來。 ——————————————————- 🎉 Happy 2025! 🎉 💝Step ahead of time with mProbe for better health! 🔆Start the new year by understanding your physiological age, managing your suboptimal health risks, preventing precancerous changes, and embracing the most accurate cancer treatment guidance. We believe that a healthier future begins with every informed decision and piece of data. ㊗️mProbe wishes you a new year filled with confidence in health, peace in decisions, and brilliance in life! ✅Let’s explore together and let science lead the way forward. #MetaGuard #BiologicalAge #Metabolimics #SubHealth #OncoOmicsDx #Proteomics #CancerTreatment
-
🔬 Exciting News! ACT Genomics, a leading precision medicine company committed to making personalized cancer care accessible across Asia, has joined forces with mProbe Inc. Taiwan Inc., a pioneer in quantitative proteomics, to revolutionize cancer diagnostics through precise clinical proteomics. This collaboration is solidified by the signing of a strategic Memorandum of Understanding (MOU). 🤝 Strategic Collaboration ACT Genomics and mProbe Inc. have signed an MOU to leverage the strengths of #proteomics and #genomics for enhanced cancer diagnostics and personalized treatment decisions across Asian markets. Through this collaboration, our #OncoOmicsDx products will be combined with ACT Genomics' market expertise and extensive network, bringing more efficient and precise diagnostic solutions to cancer patients and healthcare professionals. This marks our shared commitment to advancing the application of precision medicine across the #Asian region. 🎯 Precision at Its Best By combining ACT Genomics' #genomic and clinical expertise with mProbe Inc.'s advanced #proteomics capabilities, ACT Genomics and mProbe will work together to decode the molecular features of tumors at the DNA, RNA, and protein levels. This collaboration will provide more precise diagnoses and personalized treatment plans, delivering innovative solutions and deeper insights into cancer diagnosis and treatment for patients across #Asia, ultimately improving patient outcomes. 🔗 Click to learn more: mProbe and ACT Genomics Announce Strategic Collaboration https://lnkd.in/g_4SmTeV #PrecisionMedicine #CancerCare #Proteomics #Genomics #Oncology #HealthcareInnovation #AsiaHealthcare #mProbe #ACTGenomics #StrategicPartnership #CancerDiagnostics #OncoOmicsDx 🔬 最新消息！📊 ACT Genomics 行動基因作為精準醫療領域的領導者，致力於讓個人化癌症照護在亞洲各地普及化，現已與mProbe Inc. 台灣雲檢（mProbe Taiwan Inc.）攜手合作，透過精準的臨床蛋白質體學技術，革新癌症診斷。此次合作已簽署戰略合作備忘錄（MOU），正式展開雙方合作。 🤝 戰略合作 ACT Genomics 行動基因與 mProbe Inc. 台灣雲檢簽署 MOU，結合雙方在#基因體學 與 #蛋白質體學 上的優勢，提升癌症診斷及個人化治療決策於亞洲市場的應用。透過這次合作，我們的 #OncoOmicsDx 產品將結合 ACT Genomics 在市場上的專業知識與廣泛網絡，為癌症患者及醫療專業人員帶來更高效、更精準的診斷解決方案。這標誌著我們共同致力於提升亞洲區域內精準醫療的應用與發展！ 🎯 精準醫療的最佳實踐 透過結合#行動基因 的 #基因體學 與 #臨床專業， 及 #台灣雲檢 的先進 #蛋白質體學技術， 行動基因與台灣雲檢將攜手解析腫瘤的 #DNA、RNA 及#蛋白質層級分子特徵， 提供更精確的診斷及個人化治療方案，為#亞洲癌症患者 帶來創新的診斷解決方案及更深刻的治療洞見，以提升患者的治療成效。 🔗 點擊了解更多: mProbe 與 ACT Genomics 宣布戰略合作 https://lnkd.in/g_4SmTeV #精準醫療 #癌症診斷 #蛋白質體學 #基因體學 #醫療創新 #亞洲醫療 #行動基因 #台灣雲檢 #戰略合作 #癌症照護 #OncoOmicsDx安康奧秘
-
-
📣 #台灣雲檢 參加2024海峽兩岸檢驗醫學論壇，分享臨床蛋白質體學於個人化癌症用藥建議的應用 📣 #mProbeTW Joins 2024 Cross-Strait Clinical Laboratory Medicine Forum, Sharing Applications of Clinical Proteomics for Personalized Cancer Treatment ━━━━━━━━━━━━━━━━━━━━ 2024年10月13日，「2024海峽兩岸檢驗醫學論壇暨第24屆海峽兩岸檢驗醫學學術交流會議」在台中舉行，台灣雲檢的開發暨產品行銷總監康詩婷博士應邀參加，並發表專題演講，介紹OncoOmicsDx如何運用先進的臨床蛋白質體學技術，提供個人化癌症用藥建議。 On October 13, 2024, Dr. Bennie Kang, Director of Business Development and Product Marketing at #mProbeTW, participated in the Cross-Strait Clinical Laboratory Medicine Forum in Taichung. Dr. Kang's presentation focused on how OncoOmicsDx leverages advanced clinical proteomics to provide personalized treatment recommendations for cancer patients. ━━━━━━━━━━━━━━━━━━━━ 📢 康博士強調，OncoOmicsDx採用非抗體的絕對定量技術和高解析度質譜儀，能精準識別出標準治療未涵蓋的潛在分子靶點，特別適合第三至第四期患者，提供化療、標靶、免疫療法及臨床試驗藥物等多樣化選項，並可與NGS技術結合，為醫師和患者制定更全面的治療策略。 📢 Dr. Bennie Kang highlighted that OncoOmicsDx uses absolute quantification with high-resolution mass spectrometry, accurately identifying potential molecular targets beyond standard treatment. This makes it especially suitable for late-stage patients, offering a range of options including chemotherapy, targeted therapy, immunotherapy, and clinical trial drugs, while complementing NGS for a more comprehensive treatment strategy. ━━━━━━━━━━━━━━━━━━━━ 📌 #台灣雲檢 希望通過此次論壇，與兩岸專家攜手推動精準醫療和LDTs的發展，造福更多患者。 📌 Through this forum, mProbeTW aims to collaborate with experts across the strait to advance precision medicine and LDTs, benefiting more patients. ━━━━━━━━━━━━━━━━━━━━ 📣 #OncoOmicsDx #臨床蛋白質體學 #ClinicalProteomics #個人化治療 #PersonalizedMedicine #精準醫療 #PrecisionMedicine #LDTs #mProbeTW #癌症治療 #CancerTreatment #學術交流 #AcademicExchange #mProbe
-
-
📣 #台灣雲檢 感謝 #TIMPA台灣整合醫學推廣協會及理事長 士銘劉醫師 邀請，參與糖尿病代謝症候群精準整合醫學講座，分享MetaGuard美塔力檢測技術新知，促進健康管理與早期干預 📣 mProbeTW Partners with TIMPA to Join Precision Integrated Medicine Seminar on Diabetes & Metabolic Syndrome, Sharing MetaGuard Technology to Promote Health Management and Early Intervention ━━━━━━━━━━━━━━━━━━━━ 2024年9月1日，mProbe的事業開發暨產品行銷總監康詩婷博士在TIMPA舉辦的糖尿病及代謝症候群精準整合醫學講座中發表演講，分享了MetaGuard美塔力如何利用先進的代謝體學檢測技術，協助識別無症狀糖尿病及亞健康風險，並及早干預，促進健康管理。 On September 1, 2024, Dr. Shih-Ting Kang, Director of Business Development and Product Marketing at mProbe, presented at the TIMPA Precision Integrated Medicine Seminar on Diabetes & Metabolic Syndrome. Dr. Kang highlighted how MetaGuard leverages advanced metabolomics to detect early signs of asymptomatic diabetes and suboptimal health, enabling timely intervention. ━━━━━━━━━━━━━━━━━━━━ 📢 康詩婷博士引用臺大醫院內科部副主任王治元醫師的見解，指出許多無症狀糖尿病患者在空腹血糖異常出現前，飯後血糖便已偏高。然而，傳統健檢多僅檢測空腹血糖，可能錯失早期警訊，增加心肌梗塞、中風等慢性病發病風險。 📢 Dr. Bennie Kang cited insights from Dr. Chih-Yuan Wang, Associate Director at NTUH, emphasizing that post-meal blood glucose levels often rise years before fasting glucose does. Traditional health checks, focusing only on fasting glucose, may miss early warnings, increasing the risk of complications like heart attacks and strokes. ━━━━━━━━━━━━━━━━━━━━ 📌 MetaGuard美塔力能夠識別早期的代謝異常，即使患者無明顯症狀，也能精準定位中高風險人群。這項多體學檢測技術，還能輔助醫師更全面地評估患者的生理年齡及慢性病風險。mProbe期待透過與TIMPA的合作，促進更積極的健康管理，幫助更多人及早發現潛在健康問題，提供個性化的健康管理方案。 📌 MetaGuard identifies early metabolic changes, even in patients without visible symptoms, complementing traditional methods like HbA1c. This multi-omics testing technology also helps physicians comprehensively assess physiological age and chronic disease risks. By partnering with TIMPA, mProbe aims to enhance proactive healthcare, helping more individuals catch potential risks early and receive personalized health management solutions. ━━━━━━━━━━━━━━━━━━━━ 📣 #MetaGuard #美塔力 #代謝體學檢測 #MetabolomicsTesting #多體學檢測 #MultiOmicsTesting #生理年齡 #BiologicalAge #慢性病發病風險 #ChronicDiseaseRisk #mProbe #早期發現 #EarlyDetection #健康管理 #HealthManagement #亞健康 #SubHealth #TIMPA
-